AEON Biopharma News

12 Health Care Stocks Moving In Thursday's Pre-Market Session

GainersOneMedNet (NASDAQ:ONMD) shares moved upwards by 103.2% to $1.0 during Thursday's pre-market session. The company's market cap stands at $23.7 million. iSpecimen (NASDAQ:ISPC) stock moved upward

BenzingaMay 23 07:06

AEON Biopharma Halts Migraine Study and Evaluates Strategy

TipRanksMay 16 15:42

AEON Biopharma Price Target Cut to $6.00/Share From $18.00 by HC Wainwright & Co.

AEON Biopharma Price Target Cut to $6.00/Share From $18.00 by HC Wainwright & Co.

Dow JonesMay 15 13:14

AEON Biopharma Is Maintained at Buy by HC Wainwright & Co.

AEON Biopharma Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMay 15 13:14

HC Wainwright & Co. : The AEON Biopharma (AEON.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $18.00 to $6.00.

HC Wainwright & Co. : The AEON Biopharma (AEON.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $18.00 to $6.00.

Zhitong FinanceMay 15 13:10

HC Wainwright & Co. Maintains Buy on AEON Biopharma, Lowers Price Target to $6

HC Wainwright & Co. analyst Douglas Tsao maintains AEON Biopharma (AMEX:AEON) with a Buy and lowers the price target from $18 to $6.

BenzingaMay 15 13:04

Analysts Are Bullish on These Healthcare Stocks: AEON Biopharma (AEON), Palatin Technologies (PTN)

TipRanksMay 15 10:20

AEON Biopharma | 10-Q: Quarterly report

SEC announcementMay 14 15:46 · Announcements

AEON Biopharma Q1 2024 Adj EPS $(3.17) Misses $(0.31) Estimate

AEON Biopharma (AMEX:AEON) reported quarterly losses of $(3.17) per share which missed the analyst consensus estimate of $(0.31) by 922.58 percent.

BenzingaMay 14 15:29

Press Release: AEON Biopharma Reports First Quarter 2024 Financial Results

AEON Biopharma Reports First Quarter 2024 Financial Results -- Ongoing analysis of interim data from the Phase 2 study of ABP-450 in chronic migraine, which did not achieve its primary or secondary e

Dow JonesMay 14 15:05

AEON Biopharma | 10-K/A: Annual report (Amendment)

SEC announcementMay 14 08:09 · Announcements

AEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May Be Around the Corner

Yahoo FinanceMay 9 08:35

AEON Biopharma Provides Update on Development Pipeline

IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for

GlobeNewswireMay 9 07:00

HC Wainwright & Co. Reiterates Buy on AEON Biopharma, Maintains $18 Price Target

HC Wainwright & Co. analyst Douglas Tsao reiterates AEON Biopharma (AMEX:AEON) with a Buy and maintains $18 price target.

BenzingaMay 6 05:44

AEON Biopharma Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/06/2024 990.91% HC Wainwright & Co. → $18 Reiterates Buy → Buy 04/17/2024 990.91% HC Wainwright & Co. →

BenzingaMay 6 05:43

Maintaining Buy on AEON Biopharma: Potential of ABP-450 Despite Phase 2 Setback

TipRanksMay 6 05:18

US Equity Markets Close Higher Friday Following Weak Jobs Report

US equity markets ended higher Friday after a weak jobs report raised bets on interest rate cuts. * Nonfarm payrolls rose by 175,000 in April, well below expectations for an increase of 240,000 jobs,

MT NewswiresMay 3 15:08

Ardelyx ARDX Earnings; AEON Biopharma AEON Phase 2 Fail

BioPharmCatalystMay 3 14:46

Sector Update: Health Care

Health care stocks were mixed late Friday afternoon with the NYSE Health Care Index shedding 0.2% and the Health Care Select Sector SPDR Fund (XLV) rising 0.2%. The iShares Biotechnology ETF (IBB) cli

MT NewswiresMay 3 14:35

Top Midday Decliners

AEON Biopharma (AEON) said on Friday that its preventive treatment for chronic migraine, ABP-450, failed to meet the primary endpoint of its phase 2 trial. Shares slumped 51.5% after intraday trading

MT NewswiresMay 3 13:37